What question did this study set out to answer?

The study investigates the neuroprotective effects of everolimus on hippocampal neurons subjected to oxidative stress.

May 3, 2026Cumhuriyet Science Journal0 citationsOpen Access

Exploring the Protective Role of Everolimus in Preventing Pentylenetetrazole-Triggered Injury in Hippocampal Neurons Using the HT-22 Cell Line

FYFatih YulakSivas Cumhuriyet Üniversitesi İCİrem CinazSivas Cumhuriyet Üniversitesi

Key Points

The study investigates the neuroprotective effects of everolimus on hippocampal neurons subjected to oxidative stress.
Utilized HT-22 hippocampal cell line as an in vitro model.
Cells were divided into four groups: control, PTZ exposure, everolimus treatment, and combination of everolimus with PTZ.
Cell viability was measured using XTT assay, and oxidative stress was assessed by total antioxidant status (TAS) and total oxidant status (TOS).
Everolimus treatment at 5 and 10 nM significantly increased cell viability (p < 0.01).
In the combination group (everolimus + PTZ at 10 nM), TAS levels were significantly elevated compared to the PTZ-only group (p < 0.01).
TOS levels in the PTZ + everolimus group were significantly reduced compared to the PTZ-only group (p < 0.01).

Abstract

This study aimed to explore the neuroprotective properties of everolimus and its association with oxidative stress. The HT-22 hippocampal neuronal cell line was utilized as the in vitro model. To assess the protective effects of everolimus, four experimental groups were designed. The control group received no treatment. The pentylenetetrazol (PTZ) group was exposed to 60 mM PTZ for 1 hour. In the everolimus group, cells were treated with increasing concentrations of everolimus (0.1, 0.5, 1, 5, and 10 nM) for 2 hours. In the combination group (everolimus + PTZ), cells were pre-treated with everolimus at the same concentrations for 1 hour, followed by 60 mM PTZ exposure for an additional hour. Cell viability was assessed via the XTT assay, while oxidative stress was evaluated by measuring total antioxidant status (TAS) and total oxidant status (TOS) using commercial assay kits. Treatment with everolimus significantly enhanced cell viability at concentrations of 5 and 10 nM (p 0.01). Additionally, TAS levels were markedly elevated, and TOS levels were significantly reduced in the PTZ + everolimus (10 nM) group compared to the PTZ-only group (p 0.01). These findings suggest that everolimus confers neuroprotection by enhancing the antioxidant defense system and mitigating PTZ-induced cytotoxicity

Perguntar à IA

Bookmark

View Full Paper